THERAPY WITH JAK INHIBITORS AND THE RISK OF CARDIOVASCULAR EVENTS IN A DUTCH RHEUMATOID ARTHRITIS POPULATION

被引：0
|
作者：
Popa, C. [1 ,2 ]
Opdam, M. [1 ]
Den Broeder, N. [1 ]
Wientjes, M. [1 ]
Den Broeder, A. [1 ,2 ]
机构：
[1] Sint Maartensklin, Rheumatol, Ubbergen, Netherlands
[2] Radboudumc, Rheumatol, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Cardiovascular disease; Targeted synthetic; drugs;
D O I：
10.1136/annrheumdis-2023-eular.4033
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0221
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [31] JAK inhibitors: fate in doubt for rheumatoid arthritis?
    不详
    LANCET RHEUMATOLOGY, 2021, 3 (03): : E161 - E161
  • [32] Selective JAK inhibitors in development for rheumatoid arthritis
    Norman, Peter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (08) : 1067 - 1077
  • [33] Chemical JAK inhibitors for the treatment of rheumatoid arthritis
    Nakayamada, Shingo
    Kubo, Satoshi
    Iwata, Shigeru
    Tanaka, Yoshiya
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (16) : 2215 - 2225
  • [34] Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
    Yamaoka, Kunihiro
    Tanaka, Yoshiya
    CURRENT RHEUMATOLOGY REVIEWS, 2011, 7 (04) : 306 - 312
  • [35] RHEUMATOID ARTHRITIS TNF inhibitors and cardiovascular risk management in RA
    Pope, Janet E.
    NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (06) : 317 - U17
  • [36] CARDIOVASCULAR RISK AND STATIN THERAPY IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
    Eidner, T.
    Wolf, G.
    Oelzner, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 775 - 776
  • [37] Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
    Kotyla, Przemyslaw J.
    Islam, Md Asiful
    Engelmann, Malgorzata
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 17
  • [38] CANCERS AND CARDIOVASCULAR DISEASES IN PATIENTS WITH SEROPOSITIVE RHEUMATOID ARTHRITIS TREATED WITH JAK INHIBITORS AND BIOLOGICS
    Ahn, S. S.
    Han, M.
    Jung, I.
    Kim, H. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 87 - 88
  • [39] Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
    Avouac, Jerome
    JOINT BONE SPINE, 2022, 89 (06)
  • [40] Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Ian C. Scott
    Samantha L. Hider
    David L. Scott
    Drug Safety, 2018, 41 : 645 - 653
12345